Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen announces positive arthritis drug trial

Biogen announces positive arthritis drug trial

25th January 2008

Results from a phase three clinical study of rheumatoid arthritis treatment Rituxan have shown that patients have responded more positively to the drug than they have to prior treatment with methotrexate (MTX).

Rituxan, the brand name for the drug rituximab, was found to be a more effective biologic therapy for patients with rheumatoid arthritis in combination with MTX than treatment with MTX alone.

Dr Hal Barron, senior vice-president of Genetech, said the latest round of trials marked the first study to demonstrate the potential for the two drugs to be used together to treat rheumatoid arthritis.

“These findings support the potential use of Rituxan earlier in the course of treatment for this debilitating disease,” he added.

Some 509 randomised patients were selected to take part in the study, which took place across 11 countries around the world.

According to the National Rheumatoid Arthritis Society, the disease currently affects around 0.8 per cent of the adult population in the UK.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.